Abstract Insulin has been shown to influence intestinal structure and absorptive function. The purpose of the present study was to evaluate the effects of parenteral insulin on structural intestinal adaptation, cell proliferation, and apoptosis in a rat model of short bowel syndrome (SBS). Male Sprague-Dawley rats were divided into three experimental groups: sham rats underwent bowel transection and reanastomosis, SBS rats underwent a 75% small bowel resection, and SBS-INS rats underwent a 75% small bowel resection and were treated with insulin given subcutaneously at a dose of 1 U/kg, twice daily, from day 3 through day 14. Parameters of intestinal adaptation, enterocyte proliferation, and enterocyte apoptosis were determined on day 15 following operation. SBS rats demonstrated a significant increase in jejunal and ileal bowel and mucosal weight, villus height and crypt depth, and cell proliferation index compared with the sham group. SBS-INS animals demonstrated higher jejunal and ileal bowel and mucosal weights, jejunal and ileal mucosal DNA and protein, and jejunal and ileal crypt depth compared with SBS animals. SBS-INS rats also had a greater cell proliferation index in both jejunum and ileum and a trend toward a decrease in enterocyte apoptotic index in jejunum and ileum compared with the SBS untreated group. In conclusion, parenteral insulin stimulates structural intestinal adaptation in a rat model of SBS. Increased cell proliferation is the main mechanism responsible for increased cell mass.
Introduction
Short bowel syndrome (SBS) is defined as an intestinal failure following a loss of intestinal length below the minimal amount necessary for the absorption of nutrients and a normal nutritional status. SBS is a common problem in pediatric surgery and occurs in newborns and infants suffering from necrotizing enterocolitis, intestinal atresia, and volvulus requiring massive intestinal resection [1] . Despite the availability of total parenteral nutrition (TPN), advances in resuscitation, availability of potent antibiotics, and modern techniques of organ support, SBS remains a significant cause of infant morbidity and mortality [2] .
Although intestinal transplantation has emerged as a feasible alternative in the treatment of children with SBS in the last two decades, intestinal adaptation remains the only chance for survival in a subset of these patients. Throughout the process of adaptation, the small intestine increases its absorptive performance and its functional capacity in an attempt to meet the body's metabolic and growth needs [3] . Over the past decades, considerable research has focused on identifying those trophic factors that may augment and accelerate bowel regrowth in patients with SBS. These include nutrients and other luminal constituents, gastrointestinal secretions, hormones, and peptide growth factors [4] .
The insulin-like growth factor (IGF) family includes three peptides: insulin, insulin-like growth factor I (IGF-I), and insulin-like growth factor II (IGF-II) [5] . The recent evidence suggests that both IGF-I and IGF-II are involved in modulation of growth and differentiation of normal small bowel [6] . Olanrewaju and coworkers [7] have shown that infusion of IGF-I into the rodent ileum resulted in a twofold increase in mucosal weight and other parameters of bowel growth. Although a positive role for IGF system in postresection intestinal hyperplasia has been reported by many investigators [8, 9] , little evidence exists that insulin may affect intestinal growth following bowel resection. Recent experimental and clinical studies suggest a possible role for insulin in normal intestinal physiology. In a recent study, we have demonstrated that oral insulin promotes adaptive growth of small bowel in a rat model of SBS (unpublished data). The effect of systemic (parenteral) administration of the insulin has never been described previously. Systemic administration of exogenous hormone or growth factor may not mimic its local effect within the small bowel because of the complexities of the in vivo system [8] . The present study was undertaken to explore the effects of insulin given subcutaneously on the adaptive changes in the mucosa following massive small bowel resection in a rat.
Materials and methods

Animals
All studies were conducted in compliance with the guidelines established by the ''Guide for the Care and Use of Laboratory Animals,'' Rappaport Faculty of Medicine, Technion (Haifa, Israel). Sprague-Dawley rats weighing 250-320 g were housed in individual cages and were acclimated to laboratory conditions (22°C with 12-h light/dark cycle) for 3 days.
Twenty-four Sprague-Dawley rats were randomly assigned to three experimental groups. In group A, sham male animals underwent bowel transection and reanastomosis (sham, n=8); in group B, rats underwent 75% bowel resection (SBS, n=8); and in group C, rats underwent a 75% small bowel resection and were treated with insulin given subcutaneously at a dose of 1 U/kg, twice daily, from day 3 through day 14 (SBS-INS, n=8).
Surgical procedure
After an overnight fast, animals were anesthetized with sodium pentobarbital (45 mg/kg) administered intraperitoneally. Using sterile technique, the abdomen was opened using a midline incision. For sham animals, the intestine was divided and reanastomosed without resection at a point 15 cm proximal to the ileocecal valve. For SBS rats, a 75% resection was performed from 5 cm distal to the ligament of Treitz to 15 cm proximal to the ileocecal valve. Anastomoses were performed using interrupted sutures of 6-0 silk. In all animals the abdomen was closed in two layers with a running suture of 3-0 Dexon (Davis and Geck, NY, USA). Postoperatively, animals were allowed water ad libitum immediately after operation and normal chow at the beginning of the 1st postoperative day.
Parameters of intestinal adaptation
All animals were sacrificed on the 15th postoperative day. The small intestine from the pylorus to the ileocecal valve was removed and divided into two segments: jejunum proximal to anastomosis and terminal ileum. Each segment was weighed and cut longitudinally. Mucosa was scraped using a glass slide, collected, and weighed. Bowel and mucosal weight was calculated per cm of bowel length per 100 g of body weight as described previously [10] . DNA and protein were extracted using TRIzol reagent as described by Chomczynski [11] . The DNA concentrations were recorded spectrophotometrically and calculated per cm of bowel length. Final protein concentration was measured spectrophotometrically using a commercially available kit (Bio-Rad, Protein Assay) and was calculated per cm of bowel length.
Histological examination
Intestinal samples from the proximal jejunum and distal ileum were fixed in 10% formalin, dehydrated in progressive concentrations of ethanol, cleared in xylene, and embedded in paraffin wax. Deparaffinized 5-lm sections were stained with haematoxylin and eosin. Villus height and crypt depth were measured using a graded eye piece at 10 times magnification by a pathologist blinded to the tissue origin.
Enterocyte proliferation and apoptosis
Crypt cell proliferation determination was assessed using biotinylated monoclonal anti-BrdU antibody system provided in a kit form (Zymed Laboratories, San Francisco, CA, USA), and TUNEL assay for apoptotic cell detection was performed using the I.S. Cell Death Detection kit (Boehringer Mannheim GmbH, Mannheim, Germany). An index of proliferation was determined as the ratio of crypt cells staining positively for BrdU per 10 crypts. The apoptotic index (AI) was defined as the number of apoptotic TUNEL-positive cells per 10 villi. A qualified pathologist blinded to the source of intestinal tissue performed all measurements.
Statistical analysis
The data are expressed as the mean ± SEM. Statistical analysis of parameters of adaptation, enterocyte proliferation, and apoptosis was performed using the nonparametric Kruskal-Wallis ANOVA test, followed by the corrected Mann-Whitney test, with P less than 0.05 considered statistically significant.
Results
Body weight
The sham-operated control rats' body weight remained unchanged during the first 4 days, followed by a gradual increase in weight throughout the next 10-day observation period (Fig. 1) . Bowel resection (group B) caused a significant reduction in weight during the first 4 days, followed by a gradual increase in weight during the next 10 days. However, body weight was significantly lower in SBS rats compared with sham animals. Administration of subcutaneous insulin did not significantly change body weight gain compared with SBS untreated animals.
Overall intestinal and mucosal weights
Overall total intestinal weights expressed as g/cm of length/100 g body weight significantly increased in jejunum (threefold, P<0.05) and ileum (twofold, P<0.05) in SBS rats (group B) compared with sham (group A) animals (Fig. 2) . SBS-INS rats showed higher jejunal (31%, P<0.05) and ileal (22%, P<0.05) intestinal weight compared with SBS untreated animals. Mucosal weights showed similar changes. Resected animals (group B) showed greater mucosal weight per centimeter of bowel in jejunum (threefold, P<0.05) and ileum (twofold, P<0.05) compared with sham (group A) rats (Fig. 2) . Subcutaneous insulin injections (group C) led to an additional increase in mucosal weights in jejunum (35%, P<0.05) and ileum (33%, P<0.05) compared with SBS untreated animals (group B).
Mucosal DNA and protein
Short bowel syndrome rats (group B) had significantly higher mucosal DNA levels in jejunum (threefold, P<0.05) and ileum (33%, P<0.05) compared with sham (group A) animals (Fig. 3) . SBS-INS rats (group C) demonstrated an additional 50% increase in mucosal DNA in jejunum and ileum compared with SBS untreated animals (group B). SBS rats (group B) demonstrated a threefold increase in mucosal protein in jejunum compared with sham (group A) animals. SBS-INS rats showed a significant increase in mucosal protein in jejunum (47%, P<0.05) and ileum (55%, P<0.05) compared with SBS untreated (group B) animals.
Histological findings
The histological changes in remaining bowel are shown in Fig. 4 . As expected, bowel resection (group B) resulted in a significant increase in villus height in jejunum (50%, P<0.05) and ileum (49%, P<0.05), and in crypt depth in jejunum (29%, P<0.05) and ileum (24%, 
P<0
.05) compared with sham animals (group A). Subcutaneous injections of insulin (group C) led to a significant increase (vs. SBS untreated animals, group B) in crypt depth in jejunum (25%, P<0.05) and ileum (38%, P<0.05) and a trend toward an increase in villus height in jejunum and ileum; however, this trend did not achieve statistical significance. 262±19 BrdU-positive cells per 10 crypts, P<0.05) proliferation rates compared with SBS untreated animals (group B).
Short bowel syndrome rats showed a significant increase in enterocyte apoptosis in jejunum (21.32±3.4 vs. 9.2±3.three apoptotic cells per five villi, P<0.05) and ileum (28.2±3.4 vs. 16±5 apoptotic cells per five villi, P<0.05) compared with sham animals (Fig. 6) . Following subcutaneous insulin, SBS rats showed a tendency toward a decrease in cell apoptosis in jejunum and ileum compared with SBS untreated animals; however, this trend did not achieve statistical significance.
Discussion
The IGF system was discovered as a group of factors in serum that mediate the growth-promoting effects of growth hormone on skeleton [12] . This system includes the ligands IGF-I and IGF-II, the receptors IGFRs type 1 and type 2, and six high-affinity binding proteins (IGFBPs 1-6) that modulate IGF cellular actions [8] . The role of the IGF system in the growth and differentiation of bowel during development has been reported by many investigators [13, 14] A growing body of evidence suggests that IGF-I mediates many of the enterotrophic actions of growth hormone. It is believed that growth hormone stimulates intestinal adaptation in patients with SBS through modulation of IGF-I [9] . In many animal models of SBS, systemic or local IGF-I administration enhanced bowel regrowth and improved nutrient absorption [9, 15] . Although positive effects of IGF-I in SBS have been reported by many investigators, little evidence exists that insulin may affect intestinal growth following bowel resection. Recent experimental and clinical studies suggest a possible role for insulin in normal intestinal physiology. Insulin stimulates the epithelial cell proliferation and differentiation of intestinal epithelial cells in vitro [16] . Insulin-receptor densities are selectively associated with intestinal mucosa growth in neonatal calves [17] . Insulin has trophic effects on intestinal mucosa in the newborn miniature pig [18] , accelerates enterocytes proliferation in the intestinal mucosa of suckling mice [19] , and increases fermental activities in villus cells and the concentration of the secretory component of immunoglobulins in crypt cells in rats [20] .
Because there is some evidence that insulin has trophic effects on gut, we hypothesized that this agent could enhance intestinal regeneration following massive small bowel resection. Insulin might stimulate mucosal hyperplasia by a direct stimulation of proliferation or cell migration, or by inhibition of enterocyte apoptosis. Alternatively, it might exert its pro-adaptive effect by stimulating the release of various trophic agents or by altering absorption and secretion of different nutrients.
Our results show that bowel resection in a rat results in apparent stimulation of structural intestinal adaptation. This is evident from increased bowel and mucosal weight, mucosal DNA and protein content, villus height, and crypt depth. Our findings suggest that proliferation of crypt cells increased significantly following bowel resection and was closely correlated with increased crypt depth. An increased cell apoptosis may be considered a mechanism that counterbalances the increased enterocyte proliferation in order to reach a new homeostatic set during intestinal adaptation and promotes disposal of genetically aberrant stem cells and prevents tumorogenesis. Mucosal response to massive resection in our experiment is comparable to the changes previously observed in our laboratory [21, 22] .
In our experiment, subcutaneously administered insulin stimulated mucosal hyperplasia, characterized by increased bowel and mucosal weights and increased mucosal DNA and protein. Increases in DNA and protein content in our model suggest that hyperplasia was the predominant adaptive response to insulin administration. Increased crypt depth in both jejunum and ileum suggests increased cell proliferation and was correlated with increased enterocyte proliferation index. Enterocyte death via apoptosis showed a trend toward a decrease; however, this trend did not achieve statistical significance. Increased enterocyte proliferation and a trend toward decreased cell death suggest increased gut epithelial cell turnover following insulin administration and may indicate an adaptive mechanism to increase enterocyte mass. Taken together, these findings suggest that insulin may stimulate gut regrowth following massive small bowel resection in the rat. These preliminary observations suggest that insulin may have clinical utility for the patient with SBS.
